NASDAQ · LEXX
Healthcare · Biotechnology
$3.20
Up+$0.12 (+3.75%)
Updated Oct 9, 2026, 9:00 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LEXX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
LEXX closed at $3.20 after 21 trading sessions, down 20.99% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $3.50 | $3.6693 | $3.19 | $3.20 | 26.5K |
| Oct 7, 2026 | $3.14 | $3.59 | $3.10 | $3.46 | 76.93K |
| Oct 6, 2026 | $2.925 | $3.24 | $2.86 | $3.24 | 66.07K |
| Oct 5, 2026 | $2.90 | $3.125 | $2.77 | $2.77 | 40.22K |
| Oct 2, 2026 | $3.18 | $3.24 | $2.80 | $2.88 | 81.26K |
| Oct 1, 2026 | $3.20 | $3.25 | $2.95 | $3.09 | 48.66K |
| Sep 30, 2026 | $3.21 | $3.29 | $3.06 | $3.15 | 23.13K |
| Sep 29, 2026 | $3.28 | $3.3399 | $2.98 | $3.13 | 77.52K |
| Sep 28, 2026 | $3.25 | $3.4599 | $3.15 | $3.225 | 41.92K |
| Sep 25, 2026 | $3.455 | $3.455 | $3.15 | $3.28 | 34.21K |
| Sep 24, 2026 | $3.29 | $3.595 | $3.1419 | $3.37 | 52.96K |
| Sep 23, 2026 | $3.31 | $3.34 | $3.10 | $3.235 | 14.38K |
| Sep 22, 2026 | $3.54 | $3.84 | $3.08 | $3.22 | 107.26K |
| Sep 21, 2026 | $3.29 | $3.48 | $3.15 | $3.425 | 25.96K |
| Sep 18, 2026 | $3.25 | $3.52 | $3.15 | $3.24 | 76.32K |
| Sep 17, 2026 | $3.07 | $4.00 | $2.91 | $3.29 | 164.31K |
| Sep 16, 2026 | $3.28 | $3.47 | $2.8001 | $3.095 | 150.4K |
| Sep 15, 2026 | $3.54 | $3.9316 | $2.98 | $3.21 | 123.68K |
| Sep 14, 2026 | $3.98 | $4.15 | $3.14 | $3.55 | 178.91K |
| Sep 11, 2026 | $4.15 | $4.72 | $3.645 | $3.97 | 197.06K |
| Sep 10, 2026 | $7.00 | $7.50 | $4.04 | $4.05 | 226.22K |
The latest Smart Investors Daily articles mentioning LEXX.
Company
Market Activity
Research & News
LEXX research
Company profile and research snapshot.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 26, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 29, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 1, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 24, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 2, 2024 | HC Wainwright & Co. | Buy | — |
Generated Oct 9, 2026, 5:06 PM
Lexaria Bioscience Corp. (LEXX) surged $0.40 to gain 12.50% in Wednesday's after-market trading session, signaling renewed investor interest in the biotech stock. While specific catalysts for today's move remain unclear from available headlines, the stock's inclusion in broader healthcare sector momentum suggests positive market sentiment toward the company.
Bottom line: LEXX's 12.50% intraday surge reflects broad healthcare sector momentum, but the lack of detailed catalysts warrants caution. Investors should await official company announcements and monitor the stock's sustainability above current levels while remaining cognizant of biotech sector volatility and regulatory risks.
Yahoo · Oct 6, 2026
* Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 * Novo announces additional weight-loss in patients switching from injected to oral deliveryKELOWNA, BC / ACCESS Newswire / October 6, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.
Yahoo · Sep 17, 2026
KELOWNA, BC / ACCESS Newswire / September 17, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.
Yahoo · Sep 9, 2026
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.
Benzinga · Sep 8, 2026
U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LEXX.
